Biotechnology research continues to churn out new drugs addressing genetic drivers of cancer. While that progress gives patients more treatment options, one limitation of this approach is it takes for ...

Recursion Pharmaceuticals is laying off a fifth of its workforce in connection with a previously announced streamlining of the AI biotech’s pipeline. Shrinking the Salt Lake City-based company’s ...